CLL-11 studied first-line CLL patients

CLL-11 is a Phase III trial that established a first-line treatment for CLL patients whose age and coexisting medical conditions are representative of the CLL patient population 1,6,8,9

GAZYVA CLL-11 Patient Population Image
CLL PATIENT POPULATION
CLL-11 PATIENT POPULATION
  • 46% of patients with CLL had at least one of the following major comorbidities 9: coronary artery disease/peripheral vascular disease; cerebrovascular disease; other cardiac disease (cardiomyopathy, valvular heart disease, or atrial fibrillation); diabetes mellitus; chronic obstructive pulmonary disease/respiratory disease; and secondary malignancy (other than nonmelanomatous skin cancer)
  • Common coexisting medical conditions in CLL-11 were 6: vascular disorders (eg, hypertension, arteriosclerosis); cardiac disorders (eg, coronary artery disease, cardiac arrhythmia); and metabolic disorders (eg, diabetes mellitus, lipid metabolism disorders)

84% of CLL-11 patients assessed had an ECOG performance status of 0-1 7

GAZYVA CLL-11 ECOG PS Image